[ad_1]
NEW DELHI: Pfizer and Glenmark Pharma have joined hands to launch abrocitinib, a first-of-its-kind oral advanced systemic treatment for moderate-to-severe atopic dermatitis (AD), in India, says a company statement.
Developed by Pfizer, abrocitinib has received marketing authorization from the Central Drugs Standard Control Organization in India and is approved by the US Food and Drug Administration (FDA), European Medicines Agency (EMA), and other regulatory agencies.
Atopic dermatitis is a chronic skin disease characterized by inflammation of the skin and skin barrier defects. The persistent itching associated with moderate‐to‐severe AD disrupts daily life, impacting social interactions, work productivity, and overall well‐being, it adds.
Glenmark and Pfizer will co‐market abrocitinib in India under the brand names JABRYUS and CIBINQO, respectively.
Developed by Pfizer, abrocitinib has received marketing authorization from the Central Drugs Standard Control Organization in India and is approved by the US Food and Drug Administration (FDA), European Medicines Agency (EMA), and other regulatory agencies.
Atopic dermatitis is a chronic skin disease characterized by inflammation of the skin and skin barrier defects. The persistent itching associated with moderate‐to‐severe AD disrupts daily life, impacting social interactions, work productivity, and overall well‐being, it adds.
Glenmark and Pfizer will co‐market abrocitinib in India under the brand names JABRYUS and CIBINQO, respectively.
#Pfizer #Glenmark #launch #atopic #dermatitis #drug
